PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Mengmeng Liu

Harbin Medical University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 10, 2026 · JOURNAL ARTICLE

Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China

Frontiers in Pharmacology

A cost-effectiveness model using a partitioned survival framework in a single health-system context; lacks clinical trial data underpinning the model and does not report the source evidence for efficacy or survival inputs.

PreliminaryMengmeng Liu Tong Liu Economic and Financial Impacts of Cancer

Reported

Cost (triplet therapy)58,614.81 USD

Cost (doublet therapy)46,521.37 USD

Cost (control therapy)15,710.17 USD

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support